You’re on our free ad-supported tier. Upgrade to NewsNow Essentials now and get your favourite news platform, faster, slicker and ads free.You’re on our free tier. Upgrade to NewsNow Essentials now. Faster, slicker and ads free.You’re on our free tier. Upgrade and go ads free now!

Home
Hot Topics
Australia
World
Sport
Business
Entertainment
Science
Technology
Lifestyle

Celltrion
Biotech
Topics

Advertisement

Celltrion

Share

Top Latest Popular

Wednesday

Celltrion wins Korea phase 1 approval for Tremfya biosimilar Korea Biomedical Review 07:47 Wed, 15 Jul

Celltrion gets green light for Phase 1 clinical trial of 'Tremfya' biosimilar in South Korea Asia Today 02:00 Wed, 15 Jul

Tuesday

Celltrion’s Truxima® Approved as First Interchangeable Rituxan® Biosimilar JD Supra 20:18 Tue, 14 Jul

Advertisement

Advertisement

Celltrion licenses autoimmune disease antibody technology from Catholic University Korea Biomedical Review 02:37 Tue, 14 Jul

In the last month

Celltrion and Teva’s TRUXIMA® Becomes First Interchangeable Rituximab Biosimilar in U.S. JD Supra 17:14 Fri, 10 Jul

Celltrion’s high-margin biosimilars gain ground across Europe, strengthening H2 growth outlook Korea Biomedical Review 02:49 Fri, 10 Jul

Spotlight On: Biosimilar Litigations - July 2026 JD Supra 21:41 Thu, 09 Jul

Spotlight On: Rituxan® (rituximab) / Truxima® (rituximab-abbs) / Ruxience® (rituximab-pvvr) / Riabni™ (rituximab-arrx) - July 2026 JD Supra 17:46 Thu, 09 Jul

Celltrion draws bullish broker outlooks after second straight sales beat Korea Biomedical Review 02:27 Wed, 08 Jul

Celltrion’s Vegzelma gains preferred status at 2 major US PBMs Korea Biomedical Review 02:11 Tue, 07 Jul

Foreign stake in Celltrion up in H1 on robust earnings, IR activities The Korea Herald 01:25 Tue, 07 Jul

Celltrion's operating profit jumps 77% in Q2 on strong biosimilar sales Korea Biomedical Review 08:10 Fri, 03 Jul

Celltrion posts record Q2 sales as profitability improves The Korea Herald 05:53 Fri, 03 Jul

Celltrion Q2 operating profit jumps 77% to $278 mil. The Korea Times 05:12 Fri, 03 Jul

Advertisement

Samsung, SK lead Chungcheong investment push The Dong-a Ilbo 00:39 Fri, 03 Jul

Samsung, SK hynix and Celltrion to invest a combined 392 trillion won in Chungcheong region Korea JoongAng Daily 06:16 Thu, 02 Jul

Celltrion secures FDA’s 1st interchangeable status for Rituximab biosimilar The Korea Times 06:45 Wed, 01 Jul

Celltrion's Truxima wins FDA interchangeability designation The Korea Herald 06:06 Wed, 01 Jul

Celltrion's Truxima becomes 1st interchangeable rituximab biosimilar in US Korea Biomedical Review 01:33 Wed, 01 Jul

Celltiron posts record showing at BIO International Convention The Korea Herald 03:19 Fri, 26 Jun

[BIO USA 2026] Celltrion expands AI-driven drug development partnerships Korea Biomedical Review 02:08 Fri, 26 Jun

Advertisement

Advertisement

About our Celltrion news

Latest news on Celltrion, a biopharmaceutical company headquartered in Incheon, South Korea.

NewsNow

Our Sites

NewsNow Nigeria

NewsNow România

NewsNow Australia

Work with us

Publisher Network

Dockside Online IDE

Legal

Subscription Terms

© Copyright 1997 - 2026 NewsNow Publishing Limited. All rights reserved.

Biotech Biotech
Back to Business Biotech
- GM Food GM Food
- AbbVie AbbVie
- Amgen Amgen
- Biogen Biogen
- BioNTech BioNTech
- Celltrion Celltrion
- Genentech Genentech
- Gilead Sciences
- Illumina Illumina
- Moderna Moderna